Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorEli Lilly and Company
About this trial
The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.
Eligibility criteria
Qualifiers
Have a body mass index (BMI) of 27 kilograms per square meter (kg/m²) or higher at screening
Have a stable body weight (less than 5% body weight change) for 90 days prior to screening
Have tried at least once to lose weight through diet but were unsuccessful
Be over 50 years old
Disqualifiers
Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed greater than 1 year before screening)
Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
Have type 1 diabetes, type 2 diabetes, or any other type of diabetes
Have an active knee infection
Trial design
Treatments tested in this trial
- Eloralintide
- Placebo
Treatment groups
900 Participants
are divided into 4 treatment groupsLocations
160Argentina
CARDIAMET Investigaciones MédicasC1014ACP, Buenos Aires Argentina
Centro Médico ArsemaC1427CCL, Buenos Aires Argentina
Centro Privado de Medicina Familiar / Mindout Research1417, Buenos Aires Argentina
Organizacion Medica de InvestigacionC1015ABO, Buenos Aires Argentina
Sponsors and collaborators
Eli Lilly and Company
Lead sponsor
Source ClinicalTrials.gov